Verastem, Inc. - Common Stock (NQ:VSTM)

7.865 -0.135 (-1.69%)

Delayed Quote Updated: 10:24 AM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Verastem, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

12 Health Care Stocks Moving In Friday's Intraday Session ↗

May 26, 2023

Via Benzinga

Why Hibbett Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

May 26, 2023

Gainers Onfolio Holdings, Inc. (NASDAQ: ONFO) gained 73% to $2.02 after the company announced it completed development of a generative AI search tool.

Via Benzinga

Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib

May 25, 2023

From Verastem Oncology

Via Business Wire

Verastem: Q1 Earnings Insights ↗

May 09, 2023

Via Benzinga

Analyst Initiates Verastem With Neutral While 'Waiting For FDA Go-Ahead' ↗

March 30, 2023

Via Benzinga

Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors

May 16, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 09, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology to Participate in Upcoming Investor Conferences

May 01, 2023

From Verastem Oncology

Via Business Wire

New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting

April 26, 2023

From Verastem Oncology

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

October 19, 2022

On Wednesday, 200 companies hit new 52-week lows.

Via Benzinga

Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days

April 18, 2023

From Verastem Oncology

Via Business Wire

7 Very Undervalued Penny Stocks to Buy in April 2023 ↗

April 06, 2023

Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option.

Via InvestorPlace

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 06, 2023

From Verastem Oncology

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023 ↗

March 30, 2023

Via Benzinga

New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer

March 15, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

March 14, 2023

From Verastem Oncology

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

March 06, 2023

Via Benzinga

Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers

February 02, 2023

From Verastem Oncology

Via Business Wire

Why Smith Micro Software Shares Are Trading Lower By Over 46%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

February 27, 2023

Gainers Lucira Health, Inc. (NASDAQ: LHDX) jumped 354% to $0.6369 after the company announced FDA authorization for its at-home combination COVID-19 & flu test.

Via Benzinga

Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock

January 24, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

January 24, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 18, 2023

From Verastem Oncology

Via Business Wire

Verastem Oncology Appoints Rob Gagnon to Board of Directors

December 15, 2022

From Verastem Oncology

Via Business Wire

Cigna To Rally 15%? Plus Needham Slashes PT On This Stock By 40% ↗

November 07, 2022

Raymond James raised the price target on Cigna Corporation (NYSE: CI) from $330 to $370. Raymond James analyst John Ransom maintained a Strong Buy rating on the stock. Cigna shares rose 0.1% to $322.17...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 07, 2022

Gainers Cidara Therapeutics (NASDAQ:CDTX) shares rose 14.6% to $0.64 during Monday's pre-market session. The market value of their outstanding shares is at $44.9 million. The company's, Q3 earnings...

Via Benzinga

Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

November 03, 2022

From Verastem Oncology

Via Business Wire

10 Best Medical Stocks Under $5 ↗

October 29, 2022

The medical industry is one of the most lucrative sectors globally, and it is one that sees the highest spending in terms of research and development, and breakthrough advances through keeping up the...

Via Talk Markets

Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday ↗

October 26, 2022

Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company.

Via Benzinga

Verastem Oncology Appoints Anil Kapur to Board of Directors

October 20, 2022

From Verastem Oncology

Via Business Wire

Stocks That Hit 52-Week Lows On Monday ↗

October 10, 2022

During Monday's trading, 528 companies set new 52-week lows.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.